Ipamorelin vs MK-677 — injectable vs oral GH secretagogues
Ipamorelin and MK-677 (ibutamoren) target the same receptor — GHSR-1a, the growth-hormone secretagogue (ghrelin) receptor — but differ structurally and pharmacokinetically. Ipamorelin is a 5-amino-acid peptide requiring SC injection, half-life ~2 hours. MK-677 is a small-molecule non-peptide that's orally bioavailable with a half-life of ~24 hours, supporting once-daily oral dosing. Both produce GH release pulses with minimal cross-reactivity to cortisol, prolactin, or aldosterone. MK-677's longer half-life produces sustained 24-hour elevation of GH/IGF-1 and increases appetite via central ghrelin receptor stimulation (sometimes a desired effect, sometimes not). The convenience-vs-pulsatility trade-off is the main research-design consideration.
Side-by-side
| ipamorelin-5mg | MK-677 (Ibutamoren) | |
|---|---|---|
| Receptor | GHSR-1a (ghrelin) | GHSR-1a (same) |
| Structure | 5-amino-acid peptide | Small molecule |
| Route | SC injection | Oral |
| Half-life | ~2 hours | ~24 hours |
| Dosing in research | 1-3× daily SC | Once daily oral |
| Appetite effect | Minimal (engineered selectivity) | Marked (orexigenic) |
| Originator | Novo Nordisk (abandoned 2007) | Merck (abandoned for primary use) |
What to know
- ·MK-677's oral bioavailability is the major practical differentiator — no injection.
- ·MK-677's appetite effect is significant — research subjects routinely report 200-500 kcal/day increased intake. This is a consequence of central GHSR activation; ipamorelin was specifically engineered to avoid this central effect.
- ·MK-677 produces sustained 24-hour GH/IGF-1 elevation; ipamorelin produces pulsed release that follows daily injection.
- ·Both raise IGF-1 in trials; magnitudes are similar at adequate dose.
- ·Both are research-use only. MK-677 was investigated for sarcopenia and hip fracture but never received approval.
Where the literature diverges
Ipamorelin's clinical evidence base is small (postoperative ileus phase 2 trials). MK-677's is larger — Merck conducted multiple phase 2/3 trials in elderly sarcopenia, hip fracture recovery, and growth-hormone-deficient adults. The MK-677 literature is more mature but most trials reported modest clinical benefits despite reliable GH/IGF-1 elevation.
FAQ
MK-677 weight gain — fluid or lean mass?+
Mixed. Trials show both: short-term water retention (fluid) common in the first weeks; longer-term studies show some lean-mass gain in older adults but also fat-mass gain proportional to caloric intake. The headline 'GH-induced lean mass' framing is oversimplified.
Can I take both?+
Same receptor — the combination would not be additive; it would just provide redundant stimulation. Combination protocols pair GHSR agonists (ipamorelin OR MK-677) with GHRH analogues (sermorelin, CJC, tesamorelin), not two GHSR agonists together.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.